Source abstract
Abstract
Abstract The tumor uptake of large non‐targeted nanocarriers primarily occurs through passive extravasation, known as the enhanced permeability and retention (EPR) effect. Prior studies demonstrated improved tumor uptake and retention of 4‐arm 40 kDa star polyethylene glycol (StarPEG) polymers for cancer imaging by adding prostate‐specific membrane antigen (PSMA) targeting small molecule ligands. To test PSMA‐targeted delivery and therapeutic efficacy, StarPEG nanodrugs with/without three copies of PSMA‐targeting ligands, ACUPA, are designed and synthesized. For single‐photon emission computed tomography (SPECT) imaging and therapy, each nanocarrier is labeled with 177Lu using DOTA radiometal chelator. The radiolabeled nanodrugs, [177Lu]PEG‐(DOTA)1 and [177Lu]PEG‐(DOTA)1(ACUPA)3, are evaluated in vitro and in vivo using PSMA+ PC3‐Pip and/or PSMA– PC3‐Flu cell lines, subcutaneous xenografts and disseminated metastatic models. The nanocarriers are efficiently radiolabeled with 177Lu with molar activities 10.8–15.8 MBq/nmol. Besides excellent in vitro PSMA binding affinity (kD = 51.7 nM), the targeted nanocarrier, [177Lu]PEG‐(DOTA)1(ACUPA)3, demonstrated excellent in vivo SPECT imaging contrast with 21.3% ID/g PC3‐Pip tumors uptake at 192 h. Single doses of 18.5 MBq [177Lu]PEG‐(DOTA)1(ACUPA)3 showed complete resolution of the PC3‐Pip xenografts observed up to 138 days. Along with PSMA‐targeted excellent imaging contrast, these results demonstrated high treatment efficacy of [177Lu]PEG‐(DOTA)1(ACUPA)3 for prostate cancer, with potential for clinical translation.
Source: crossref · Quality: baseline
Affiliations
Department of Radiology and Biomedical Imaging University of California San Francisco CA 94143 USA
National Institute of Pharmaceutical Education and Research Raebareli Lucknow UP 226002 India
ProLynx Inc. San Francisco CA 94158 USA
Helen Diller Family Comprehensive Cancer Center University of California San Francisco San Francisco CA 94143‐0981 USA
Division of Vascular and Endovascular Surgery University of California San Francisco CA 94143‐0957 USA
Department of Pathology University of California San Francisco CA 94143 USA
Department of Pharmaceutical Chemistry University of California San Francisco CA 94158‐2517 USA
Department of Biochemistry and Biophysics University of California San Francisco CA 94158 USA
Funding
Science, Mathematics, And Research For Transformation Scholarship Program